表紙
市場調查報告書

製藥產業,生物科技產業,診斷技術產業的授權的條件與契約

Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2019

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 307394
出版日期 內容資訊 英文 1700 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
製藥產業,生物科技產業,診斷技術產業的授權的條件與契約 Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2019
出版日期: 2019年04月01日內容資訊: 英文 1700 Pages
簡介

本報告提供生命科學相關的產業上開展國際事業的有力企業簽訂的授權合約的趨勢和結構詳細介紹,契約的案例研究,財務關係的主要指標,授權合約相關資料,生物醫藥品廠商與其聯盟對象對美證券交易委員會提交的實際的授權合約文件的鏈接等,廣泛網羅有助於製藥公司和生物科技企業順利進行契約談判的資訊。

摘要整理

第1章 簡介

第2章 授權合約的趨勢

  • 簡介
  • 授權合約定義
  • 成功引導授權合約的要素
  • 授權發揮有效性的場面
  • 授權合約的特性
  • 授權合約的趨勢
  • 授權選擇
  • 共同販賣促進活動相關條款的追加
  • 今後的授權合約

第3章 授權合約結構概要

  • 簡介
  • 純粹的多零組件授權合約
  • 純粹的授權合約結構
    • 授權合約範例
      • 案例研究1:Ignyta - Nerviano Medical Sciences
      • 案例研究2:Sanofi - Pozen
  • 成為廣泛合夥協議的一部分的各種權利的授權
    • 授權條款範例
      • 案例研究3:4D Molecular Therapeutics - UniQure
      • 案例研究4:Kyowa Hakko Kirin-Ultragenyx Pharmaceuticals
    • 授權合約的選擇權條款範例
      • 案例研究5:Forest Laboratories - Trevena)
      • 案例研究6:Abbvie - Receptos

第4章 主要授權合約

  • 簡介
  • 契約額大的授權合約

第5章 積極簽定授權契約的50家企業

  • 簡介
  • 積極簽定授權契約的企業

第6章 授權合約條件的基準

  • 簡介
  • 契約的總額
  • 預付款金
  • 目標達成褒獎金
  • 權利金費率

第7章 授權合約要覽

  • 簡介
  • 授權合約彙編

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2063

The Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2019 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies

Description

The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of licensing agreements from 2014 to 2019.

There has been a long standing willingness for parties to enter licensing deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

Licensing is a specific type of partnering deal whereby the parties to the deal agree to commercialize a compound, product or technology.

Specifically, licensing is the granting of permission to use intellectual property rights, such as trademarks, patents, or technology, under defined conditions

There are several forms of licensing deal. Traditional licensing arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subsequent sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful period of collaboration on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the licensing agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

Other forms of licensing such as sub-licensing and cross-licensing are also explored, with examples provided together with listing of recent deals in pharma, biotech and diagnostics.

The report provides a detailed understand and analysis of how and why companies enter licensing deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all licensing deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of licensing deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading licensing deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a review of the top 50 most active biopharma companies in licensing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a comprehensive review of licensing financials for deals announced since 2014, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.

Chapter 7 provides a comprehensive and detailed review of licensing deals signed and announced since 2014 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in licensing deal making since 2014.

In addition, a comprehensive appendix is provided organized by licensing company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing partnering in the research, development and commercialization of technologies and products.

Key benefits

Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 provides the reader with the following key benefits:

  • In-depth understanding of licensing partnering deal trends since 2014
  • Analysis of the structure of licensing agreements with numerous real life case studies
  • Comprehensive listing of over 4,500 licensing deals since 2014, together with deal terms, value and press release
  • Comprehensive access to actual licensing contracts entered into by the world's life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a licensing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.

Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 includes:

  • Trends in licensing dealmaking in the biopharma industry since 2014
  • Analysis of licensing deal structure
  • Case studies of real-life licensing deals
  • Comprehensive listing of over 4,500 licensing deals since 2014
  • Access to licensing contract documents
  • Key financial bnchmarks for headline, upfront, milestone and royalty rates
  • The leading licensing deals by value since 2014
  • Most active licensing dealmakers since 2014
  • The leading licensing partnering resources

In Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2019 provides the reader with the following key benefits:

  • In-depth understanding of licensing partnering deal trends since 2014
  • Insight into the terms included in a licensing agreement, together with real world clause examples
  • Identify leading licensing deals by value since 2014
  • Identify the most active licensing dealmakers since 2014
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Full listing of licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
  • Comprehensive access to over 4,500 licensing deals entered into by the world's biopharma companies, together with contract documents if available
  • Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing deal making

  • 2.1. Introduction
  • 2.2. Definition of licensing deals
  • 2.3. Success factors for licensing deals
  • 2.4. When licensing can be useful
  • 2.5. Attributes of licensing deals
  • 2.6. Trends in licensing deals since 2014
    • 2.6.1. Licensing deal making by year since 2014
    • 2.6.2. Licensing deal making by phase of development since 2014
    • 2.6.3. Licensing deal making by industry sector since 2014
    • 2.6.4. Licensing deal making by therapy area since 2014
    • 2.6.5. Licensing deal making by technology type since 2014
    • 2.6.6. Licensing deal making by most active company since 2014
  • 2.7. Option to license
  • 2.8. Adding co-promotion to the mix
  • 2.9. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

  • 3.1. Introduction
  • 3.2. Pure versus multi-component licensing deals
  • 3.3. Pure licensing agreement structure
    • 3.3.1. Example licensing agreements
    • 3.3.1.a. Case study 1: Ignyta - Nerviano Medical Sciences
    • 3.3.1.b. Case study 2: Sanofi - Pozen
  • 3.4. Licensing rights as part of a wider alliance agreement
    • 3.4.1. Example licensing clauses
    • 3.4.1.a. Case study 3: 4D Molecular Therapeutics - UniQure
    • 3.4.1.b. Case study 4: Kyowa Hakko Kirin - Ultragenyx Pharmaceuticals
    • 3.4.2. Example licensing option right clauses
    • 3.4.2.a. Case study 5: Forest Laboratories - Trevena
    • 3.4.2.b. Case study 6: Abbvie - Receptos

Chapter 4 - Leading licensing deals

  • 4.1. Introduction
  • 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

  • 5.1. Introduction
  • 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deal term financials

  • 6.1. Introduction
  • 6.2. Licensing partnering headline values
  • 6.3. Licensing deal upfront payments
  • 6.4. Licensing deal milestone payments
  • 6.5. Licensing royalty rates

Chapter 7 - Licensing contract directory since 2014

  • 7.1. Introduction
  • 7.2. Licensing deals with contracts since 2014

Appendices

  • Appendix 1 - Licensing dealmaking by companies A-Z
  • Appendix 2 - Licensing dealmaking by industry sector
  • Appendix 3 - Licensing dealmaking by stage of development
  • Appendix 4 - Licensing dealmaking by therapy area
  • Appendix 5 - Licensing dealmaking by technology type
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Definition of licensing
  • Figure 2: Situations where licensing can prove useful
  • Figure 3: Key attributes of a licensing deal
  • Figure 4: Trends in licensing deal announcements since 2014
  • Figure 5: Licensing deals signed at each phase of development since 2014
  • Figure 6: Licensing deals by industry sector since 2014
  • Figure 7: Licensing deals by therapy area since 2014
  • Figure 8: Licensing deals by technology type since 2014
  • Figure 9: Top 25 most active licensing dealmakers sinnce 2014
  • Figure 10: Licensing agreements - what should a contract include?
  • Figure 11: Components of the licensing deal structure
  • Figure 12: Top licensing deals by value since 2014
  • Figure 13: Most active licensing dealmakers since 2014
  • Figure 14: Licensing deals with a headline value
  • Figure 15: Licensing deals with an upfront value
  • Figure 16: Licensing deals with a milestone value
  • Figure 17: Licensing deals with a royalty rate value
Back to Top